INT279381

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 2.70
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Ms4a1)
Ms4a1 (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 6 5.00 Very Low Very Low Very Low
vincristine 6 5.00 Very Low Very Low Very Low
dexamethasone 6 5.00 Very Low Very Low Very Low
palliative 2 5.00 Very Low Very Low Very Low
Central nervous system 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
intrathecal 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Chronic Lymphoid Leukemia 28 99.44 Very High Very High Very High
Lymphatic System Cancer 164 97.72 Very High Very High Very High
Multiple Myeloma 16 82.36 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 8 77.96 Quite High
Htlv Types I And Ii 10 77.76 Quite High
Disease 78 77.56 Quite High
Mantle-cell Lymphoma 26 68.00 Quite High
Follicular Lymphoma 26 66.96 Quite High
Cancer 26 56.32 Quite High
Recurrence 20 7.00 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Alemtuzumab, an anti-CD52 antibody, has been approved for the treatment of CLL, and radioimmunoconjugates targeting CD20 are in use for patients with follicular and transformed lymphoma and also for other lymphoma subtypes.
Regulation (targeting) of CD20 associated with chronic lymphoid leukemia and lymphatic system cancer
1) Confidence 0.15 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.48 Pain Relevance 0
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
Regulation (targeting) of CD20
2) Confidence 0.15 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.22 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox